ALNYLAM PHARMACEUTICALS INC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 192,172 | $51,890,393 | 0.25% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 9, 2025 |
| June 30, 2025 | 186,905 | $60,947,949 | 0.26% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 12, 2025 |
| Sept. 30, 2025 | 87,908 | $40,085,849 | 0.17% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 12, 2025 |
| Dec. 31, 2025 | 93,444 | $37,158,099 | 0.15% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 11, 2026 |
| March 31, 2026 | 245,539 | $81,241,478 | 0.34% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 11, 2026 |
| June 30, 2026 | 252,383 | $75,974,872 | 0.25% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 12, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.